<DOC>
	<DOCNO>NCT00776022</DOCNO>
	<brief_summary>An open label , randomize , single-center , single-dose , two-treatment , two-period , crossover bioavailability study compare Cetirizine Hydrochloride 10 mg tablet Ohm Laboratories Inc. ( A subsidiary Ranbaxy , Inc ) Zyrtec® Cetirizine Hydrochloride , 10 mg tablet Pfizer Labs ( Division Pfizer Inc. ) healthy , adult , human subject feed condition</brief_summary>
	<brief_title>Bioequivalence Study Cetirizine Hydrochloride 10mg Tablets Under Fed Conditions</brief_title>
	<detailed_description>The study conduct open label , randomize , single-center , single-dose , two-treatment , two-period , crossover bioavailability test formulation cetirizine hydrochloride tablet Ohm Laboratories Inc. ( A subsidiary Ranbaxy , Inc ) contain 10 mg cetirizine hydrochloride study compare marketed product , Zyrtec® , contain 10 mg cetirizine hydrochloride Pfizer Labs ( Division Pfizer Inc. ) , healthy , adult , human , subject feed condition . Safety measure perform throughout study include physical examination , laboratory evaluation , measurement vital sign . A total 32 subject randomize receive single oral dose cetirizine hydrochloride 10 mg tablet 29 subject complete period study .</detailed_description>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>Aged 1850 year . Were within 18 29.9 kilograms/m2 per BMI ( Determination Body Mass Index ) . Had voluntarily give write informed consent participate study . Were normal health determine medical history physical examination subject perform within 30 day prior commencement study . Blood chemistry , hematology , urinalysis test perform within 30 day prior start study must within clinically acceptable limit upon evaluation Investigator . Subjects must screen checkin ( period ) blood pressure pulse rate within protocol specify range . If female childbearing potential , subject counsel importance become pregnant study , subject negative pregnancy test pretreatment visit . History clinically significant organsystem ( cardiovascular , neurological , hepatic , hematopoietic , pulmonary , endocrine , gastrointestinal ) disorder , ongoing infectious disease . history alcohol abuse drug addiction require treatment within last 12 month . Presence history renal impairment chronic liver disease . History jaundice ( yellow skin white eye ) . Participation investigationaldrug study donation blood within 30 day prior start study . Known allergy sensitivity cetirizine ( Zyrtec® ) , relate drug hydroxyzine ( Vistaril® Ataraxl® ) . Prescription drug use ( exclude hormonal contraceptive ) within 14 day prior drug administration , period . Subject take macrolide antibiotic , erythromycin , azithromicin , ketoconazole , relate drug . Ingestion grapefruit juice grapefruitcontaing product within 72 hour prio drug administration , period . Alcohol consumption 24 hour prior drug administration , period . Caffeine xanthine consumption least 10 hour prior drug administration , period . Female subject pregnant nursing . Positive HIV 1 , Hepatitis B surface antigen , urine screen drug abuse within 30 day prior start study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Bioequivalence Cetirizine Hydrochloride 10 mg tablet feed condition</keyword>
</DOC>